{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:56Z","timestamp":1791335636733,"version":"4.3.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01949-9","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:46:37Z","timestamp":1763433997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis reveals prognostic gene set that could impacts the response to chemotherapy and immunotherapy outcomes in malignant pleural mesothelioma"],"prefix":"10.1007","volume":"26","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"7","key":"1949_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jtho.2017.04.002","volume":"12","author":"B Liu","year":"2017","unstructured":"Liu B, van Gerwen M, Bonassi S, Taioli E. International association for the study of lung cancer mesothelioma task, epidemiology of environmental exposure and malignant mesothelioma. J Thorac Oncol. 2017;12(7):1031\u201345.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1949_CR2","first-page":"402","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR Jr., Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402\u201329.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1949_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","volume":"13","author":"L Mutti","year":"2018","unstructured":"Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, et al. Scientific advances and new frontiers in mesothelioma therapeutics. J Thorac Oncol. 2018;13(9):1269\u201383.","journal-title":"J Thorac Oncol"},{"issue":"14","key":"1949_CR4","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1949_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"1949_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61040638","author":"Z Kalkan","year":"2025","unstructured":"Kalkan Z, Ebinc S, Arcagok M, Bilici A, Yildiz O, Kilickap S, et al. Efficacy of immunotherapy versus chemotherapy in advanced pleural mesothelioma: a Turkish Oncology Group (TOG) study. Medicina (Kaunas). 2025. https:\/\/doi.org\/10.3390\/medicina61040638.","journal-title":"Medicina (Kaunas)"},{"key":"1949_CR7","doi-asserted-by":"publisher","first-page":"103698","DOI":"10.1016\/j.critrevonc.2022.103698","volume":"174","author":"G Bronte","year":"2022","unstructured":"Bronte G, Procopio AD, Graciotti L. The application of cancer stem cell model in malignant mesothelioma. Crit Rev Oncol Hematol. 2022;174:103698.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1949_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155432","author":"S Burgio","year":"2020","unstructured":"Burgio S, Noori L, Marino Gammazza A, Campanella C, Logozzi M, Fais S, et al. Extracellular vesicles-based drug delivery systems: a new challenge and the exemplum of malignant pleural mesothelioma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155432.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1949_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","volume":"22","author":"BCJ Cho","year":"2021","unstructured":"Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A, et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021;22(2):190\u20137.","journal-title":"Lancet Oncol"},{"key":"1949_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","volume":"64","author":"S Khan","year":"2020","unstructured":"Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020;64:93\u2013101.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1949_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","volume":"30","author":"B Wadowski","year":"2020","unstructured":"Wadowski B, De Rienzo A, Bueno R. The molecular basis of malignant pleural mesothelioma. Thorac Surg Clin. 2020;30(4):383\u201393.","journal-title":"Thorac Surg Clin"},{"issue":"4","key":"1949_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/0008-5472.CAN-19-1633","volume":"80","author":"M Marques","year":"2020","unstructured":"Marques M, Tranchant R, Risa-Ebri B, Suarez-Solis ML, Fernandez LC, Carrillo-de-Santa-Pau E, et al. Combined MEK and PI3K\/p110beta inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features. Cancer Res. 2020;80(4):843\u201356.","journal-title":"Cancer Res"},{"issue":"10026","key":"1949_CR13","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. French cooperative thoracic, bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","journal-title":"Lancet"},{"issue":"1","key":"1949_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","volume":"35","author":"S Dacic","year":"2022","unstructured":"Dacic S. Pleural mesothelioma classification-update and challenges. Mod Pathol. 2022;35(1):51\u20136.","journal-title":"Mod Pathol"},{"issue":"4","key":"1949_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgz004","volume":"40","author":"M Van Gerwen","year":"2019","unstructured":"Van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig KE, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40(4):529\u201336.","journal-title":"Carcinogenesis"},{"issue":"11","key":"1949_CR16","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5(11):1841\u20138.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1949_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407\u201316.","journal-title":"Nat Genet"},{"key":"1949_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fonc.2019.00078","volume":"9","author":"JG Zhou","year":"2019","unstructured":"Zhou JG, Zhong H, Zhang J, Jin SH, Roudi R, Ma H. Development and validation of a prognostic signature for malignant pleural mesothelioma. Front Oncol. 2019;9:78.","journal-title":"Front Oncol"},{"issue":"4","key":"1949_CR19","doi-asserted-by":"publisher","first-page":"200","DOI":"10.21037\/atm-22-527","volume":"10","author":"X Zhang","year":"2022","unstructured":"Zhang X, Huang X, Wang Z, Zhang K. Establishment and validation of a novel immune-related prognostic signature in malignant pleural mesothelioma. Ann Transl Med. 2022;10(4):200.","journal-title":"Ann Transl Med"},{"key":"1949_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3389\/fgene.2020.00899","volume":"11","author":"Y Bai","year":"2020","unstructured":"Bai Y, Wang X, Hou J, Geng L, Liang X, Ruan Z, et al. Identification of a five-gene signature for predicting survival in malignant pleural mesothelioma patients. Front Genet. 2020;11:899.","journal-title":"Front Genet"},{"key":"1949_CR21","doi-asserted-by":"publisher","first-page":"116863","DOI":"10.1016\/j.biopha.2024.116863","volume":"176","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Yang S, Dai W, Xue P, Sun Y, Wang J, et al. The role of pyroptosis in metabolism and metabolic disease. Biomed Pharmacother. 2024;176:116863.","journal-title":"Biomed Pharmacother"},{"key":"1949_CR22","doi-asserted-by":"publisher","first-page":"116247","DOI":"10.1016\/j.biopha.2024.116247","volume":"172","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Zeng W, Chen Y, Zhu X. The effect of lipid metabolism on cuproptosis-inducing cancer therapy. Biomed Pharmacother. 2024;172:116247.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1949_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"issue":"5","key":"1949_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","volume":"20","author":"A de Reyni\u00e8s","year":"2014","unstructured":"de Reyni\u00e8s A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res. 2014;20(5):1323\u201334.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1949_CR25","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333.","journal-title":"Nat Commun"},{"issue":"5","key":"1949_CR26","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","volume":"17","author":"JL Sauter","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608\u201322.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1949_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","volume":"11","author":"A Bill\u00e9","year":"2016","unstructured":"Bill\u00e9 A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11(2):249\u201355.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1949_CR28","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/thoraxjnl-2020-215027","volume":"75","author":"NI Kanellakis","year":"2020","unstructured":"Kanellakis NI, Asciak R, Hamid MA, Yao X, McCole M, McGowan S, et al. Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments. Thorax. 2020;75(11):1004\u20138.","journal-title":"Thorax"},{"issue":"1","key":"1949_CR29","doi-asserted-by":"publisher","first-page":"108597","DOI":"10.1016\/j.celrep.2020.108597","volume":"34","author":"P Chen","year":"2021","unstructured":"Chen P, Hsu WH, Han J, Xia Y, DePinho RA. Cancer stemness meets immunity: from mechanism to therapy. Cell Rep. 2021;34(1):108597.","journal-title":"Cell Rep"},{"issue":"8","key":"1949_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-021-00366-w","volume":"21","author":"D Bayik","year":"2021","unstructured":"Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21(8):526\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"1949_CR31","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","volume":"69","author":"Y Goto","year":"2009","unstructured":"Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23):9073\u201382.","journal-title":"Cancer Res"},{"key":"1949_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091270","author":"A Argentiero","year":"2019","unstructured":"Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, et al. Skeletal metastases of unknown primary: biological landscape and clinical overview. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091270.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1949_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","volume":"120","author":"AM Conway","year":"2019","unstructured":"Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in carcinoma of unknown primary (CUP): taking the \u2018U\u2019 out of \u2018CUP.\u2019 Br J Cancer. 2019;120(2):141\u201353.","journal-title":"Br J Cancer"},{"issue":"4","key":"1949_CR34","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"T Sato","year":"2018","unstructured":"Sato T, Sekido Y. NF2\/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19(4):988.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1949_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jmoldx.2021.04.002","volume":"23","author":"L Bertero","year":"2021","unstructured":"Bertero L, Righi L, Collemi G, Koelsche C, Hou Y, Stichel D, et al. DNA methylation profiling discriminates between malignant pleural mesothelioma and neoplastic or reactive histologic mimics. J Mol Diagn. 2021;23(7):834\u201346.","journal-title":"J Mol Diagn"},{"issue":"2","key":"1949_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2019;14(2):276\u201387.","journal-title":"J Thorac Oncol"},{"issue":"13","key":"1949_CR37","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343\u201373.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1949_CR38","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jtho.2018.07.007","volume":"13","author":"DA Fennell","year":"2018","unstructured":"Fennell DA. Programmed death 1 blockade with Nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1436\u20137.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"1949_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260\u201370.","journal-title":"Lancet Respir Med"},{"key":"1949_CR40","first-page":"100232","volume":"25","author":"P Markowitz","year":"2020","unstructured":"Markowitz P, Patel M, Groisberg R, Aisner J, Jabbour SK, De S, et al. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treat Res Commun. 2020;25:100232.","journal-title":"Cancer Treat Res Commun"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01949-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:46:38Z","timestamp":1763433998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01949-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1949"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01949-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"22"}}